What is he best known for?
The fields of study he is best known for:
The scientist’s investigation covers issues in Genetics, Mutation, LMNA, Progeria and Lamin.
In his research, Nicolas Lévy performs multidisciplinary study on Genetics and Premature aging.
Nicolas Lévy has researched Mutation in several fields, including Genetic variation and Cell biology.
His LMNA research incorporates elements of Nuclear lamina and Emerin.
His work carried out in the field of Progeria brings together such families of science as Progerin, Phenocopy and Bioinformatics.
The various areas that he examines in his Mandibuloacral dysplasia study include Molecular biology, Compound heterozygosity and Pathology.
His most cited work include:
- Lamin a truncation in hutchinson-gilford progeria (1073 citations)
- Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. (465 citations)
- Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. (318 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Genetics, Gene, Mutation, Pathology and Progeria.
LMNA, Phenotype, Missense mutation, Dysferlin and Exon are the primary areas of interest in his Genetics study.
His Gene study combines topics in areas such as Molecular biology, Muscular dystrophy and Disease.
Many of his studies on Mutation involve topics that are commonly interrelated, such as Genetic heterogeneity.
His work deals with themes such as Lamin, Progerin, Restrictive dermopathy and Cell biology, which intersect with Progeria.
His Lamin study integrates concerns from other disciplines, such as Cancer research and Nuclear lamina.
He most often published in these fields:
- Genetics (49.87%)
- Gene (23.48%)
- Mutation (19.00%)
What were the highlights of his more recent work (between 2016-2021)?
- Genetics (49.87%)
- Gene (23.48%)
- Cell biology (15.30%)
In recent papers he was focusing on the following fields of study:
Genetics, Gene, Cell biology, Phenotype and Missense mutation are his primary areas of study.
The various areas that Nicolas Lévy examines in his Cell biology study include Chromatin, Progerin and Progeria.
His research integrates issues of Progeroid syndromes, Annexin and Hutchinson Gilford Progeria Syndrome in his study of Progeria.
His Phenotype study combines topics in areas such as Mutation, STIM1, Disease and Neuroscience.
His Missense mutation research integrates issues from Limb-girdle muscular dystrophy and Exon.
Nicolas Lévy studied Mandibuloacral dysplasia and Pathology that intersect with LMNA.
Between 2016 and 2021, his most popular works were:
- Random walk with restart on multiplex and heterogeneous biological networks (65 citations)
- De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and abrogate nasal development (53 citations)
- MG132‐induced progerin clearance is mediated by autophagy activation and splicing regulation (51 citations)
In his most recent research, the most cited papers focused on:
Nicolas Lévy mostly deals with Genetics, Phenotype, Missense mutation, Disease and Gene.
Allele, Genetic counseling, Limb-girdle muscular dystrophy, Gene duplication and Subtelomere are among the areas of Genetics where the researcher is concentrating his efforts.
While the research belongs to areas of Allele, he spends his time largely on the problem of Epigenetics, intersecting his research to questions surrounding Mutation.
His studies deal with areas such as Exome sequencing, Exome, Barrier to autointegration factor 1 and Bioinformatics as well as Missense mutation.
Nicolas Lévy combines subjects such as Cholestasis, Immunology, Diarrhea and Myosin with his study of Gene.
His studies in MG132 integrate themes in fields like Lamin, LMNA and Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
